Relay Therapeutics Reports Third Quarter 2024 Financial Results and Corporate Highlights
Reported interim RLY-2608 data demonstrating 9.2-month median PFS in heavily pre-treated patients with PI3Kα-mutated, ...
Olema Oncology Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Presented compelling new preclinical data demonstrating anti-tumor activity for OP-3136, a novel KAT6 inhibitor, with enhanced activity of palazestrant combinations at EORTC-NCI-AACR Symposium on Mole ...
The Chronicle11h
Pratt professor receives $10.4 million Defense Department grant for breast cancer research
The 2024 Innovator Award will cover four years of Ramanujam and her team’s work to reduce the burdens of cancer treatments on ...
Clinical trial shows immunotherapy drug pembrolizumab improves outcomes for patients with soft tissue sarcoma
Addition of the immunotherapy drug pembrolizumab to standard of care for patients with advanced soft tissue sarcoma of the ...
News Medical16h
New treatment combination improves outcomes for small cell bladder and prostate cancer patients
A research team led by UCLA Health Jonsson Comprehensive Cancer Center investigators has shown that that combining pembrolizumab, an immunotherapy drug, with standard chemotherapy can improve ...
Science Daily18h
'Moonlighting' enzymes can lead to new cancer therapies
Researchers reveal that metabolic enzymes known for their roles in energy production and nucleotide synthesis are taking on unexpected 'second jobs' within the nucleus, orchestrating critical ...
Science Daily19h
Tumor suppressor forms gel-like assemblies to sacrifice cancer cells
Scientists uncovered a previously unrecognized tumor suppression mechanism through the study of condensates and ribosome formation.
Combination approach shows promise for treating rare, aggressive cancers
A research team led by UCLA Health Jonsson Comprehensive Cancer Center investigators has shown that combining pembrolizumab, ...